Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Expenditures (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Capital Expenditures for 3 consecutive years, with $1.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed 0.0% to $1.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60568.0 through Dec 2025, down 23.41% year-over-year, with the annual reading at $60568.0 for FY2025, 23.41% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1.0 at bioAffinity Technologies, up from -$3646.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $50786.0 in Q1 2025, with the low at -$13442.0 in Q4 2023.
  • Average Capital Expenditures over 3 years is $13546.1, with a median of $6635.5 recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 5468.05% in 2024, then tumbled 138.75% in 2025.
  • Over 3 years, Capital Expenditures stood at -$13442.0 in 2023, then soared by 100.01% to $1.0 in 2024, then changed by 0.0% to $1.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.0, -$3646.0, and $13427.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.